Abequolixron zinc is under clinical development by Inspirna and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abequolixron zinc’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Abequolixron zinc overview

RGX-104 is under development for the treatment of epithelial ovarian cancer, glioblastoma multiforme, solid tumors, non-small cell lung cancer, small-cell lung cancer, lymphoma (resistant to systemic therapy) and endometrial cancer. The drug candidate is administered orally. It is a small molecule. RGX-104 selectively targets Liver X Receptor (LXR) to activate APOE (Apolipoprotein E) protein expression. It was also  under development for the treatment of metastatic melanoma, urothelial cell carcinoma, triple negative breast cancer, renal cell carcinoma and transitional cell carcinoma (Urothelial Cell Carcinoma) and high grade-neuroendocrine tumors.

Inspirna overview

Inspirna, formerly Rgenix Inc is a clinical-stage biopharmaceutical company that develops novel drugs that target key pathways in cancer progression. The company’s lead drug candidate RGX-104, is a small molecule immunotherapy which targets the immune system to treat cancer progression. Its pipeline drug candidates include RGX-202, a small molecule that inhibits a novel cancer metabolism. Inspirna also discovers several novel cancer targets that drive tumor growth and cancer progression. The company also develops drugs for lung cancer, colorectal cancer, glioblastoma and triple-negative breast cancer, among others. It also conducts multiple programs in the preclinical development of drugs in the field of oncology. Inspirna is headquartered in New York City, New York, the US.

For a complete picture of Abequolixron zinc’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.